Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 3/20 | 0.35 |
| ▸ | CTSB | P07858 | 3/20 | 0.35 |
| ▸ | CTSH | P09668 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 2/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1741876 | 1.00 | CTSK (0.37) | CTSKTSHRTHRBCTSLCTSB | |
| SCHEMBL1711658 | 0.96 | CTSK (0.41) | CTSKTSHRCTSLCTSBCTSH | |
| SCHEMBL1711656 | 0.96 | CTSK (0.41) | CTSKTSHRCTSLCTSBCTSH | |
| SCHEMBL4452637 | 0.94 | CTSK (0.43) | CTSKTSHRCTSLCTSBCTSH | |
| SCHEMBL1711503 | 0.94 | CTSK (0.43) | CTSKTSHRCTSLCTSBCTSH | |
| SCHEMBL1711505 | 0.94 | CTSK (0.43) | CTSKTSHRCTSLCTSBCTSH | |
| SCHEMBL30027334 | 0.92 | SMN1; SMN2 (0.34) | CTSKTSHRTHRB | |
| SCHEMBL1711663 | 0.83 | PIK3CD (0.33) | ALDH1A1KMT2A | |
| SCHEMBL21551149 | 0.83 | CPN1 (0.45) | TSHRALDH1A1 | |
| SCHEMBL1711666 | 0.83 | PIK3CD (0.33) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071606-B2 | Substituted pyrazinone amides useful for activation of glucokinase | PFIZER INC. (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2389374-A1 | SUBSTITUTED PYRAZINONE AMIDES | Pfizer Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20110254560-A1 | Electrical Systems and Battery Assemblies | KDT ACL INVESTMENTS, LLC | 2011-10-20 | — | — | US | disclosed |
| WO-2010084428-A1 | SUBSTITUTED PYRAZINONE AMIDES | PFIZER INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20100184777-A1 | Substituted Pyrazinone Amides | PFIZER INC | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184777-A1 | Substituted Pyrazinone Amides | GCK, GCKR, PDK2 | CTSK 259/4885TSHR 1124/4885THRB 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.